Ignite Creation Date:
2025-12-24 @ 7:39 PM
Ignite Modification Date:
2025-12-25 @ 5:19 PM
Study NCT ID:
NCT01297803
Status:
UNKNOWN
Last Update Posted:
2011-02-17
First Post:
2011-01-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Comparison of Two Method Antimetabolites Application on Corneal Function in Trabeculectomy Surgery
Sponsor:
Shahid Beheshti University of Medical Sciences
Organization:
Study Overview
Official Title:
Corneal Endothelial Cell Loss Following Trabeculectomy With mitomycin_c Application Before Versus After Sclera Flap Dissection
Status:
UNKNOWN
Status Verified Date:
2010-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Application of antimetabolite agents such as mitomycin\_c has improved trabeculectomy results and better control of intraocular pressure complications such as corneal endothelial cell loss. However, Mitomycin\_c can be applied remain a concern before or after sclera flap dissection. Mitomycin\_c application after sclera flap dissection probably increases corneal endothelial cell loss. This study compares Mitomycin\_c application two methods: before and after sclera flap dissection with regard to success rate and complication. patients on base of Mitomycin\_c application time (1-2-3) minutes will be match randomise in to two groups( before and after sclera flap dissection) corneal. Endothelial cell density, polymorphism, polymegathism and intraocular pressure before and one month, three months, six months after surgery will measured.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: